Publication: Radiolabelled $^{177}$Lu-Bispidine-Trastuzumab for Targeting Human Epidermal Growth Factor Receptor 2 Positive Cancers
Radiolabelled $^{177}$Lu-Bispidine-Trastuzumab for Targeting Human Epidermal Growth Factor Receptor 2 Positive Cancers
Date
Date
Date
Citations
Cieslik, P. A., Klingler, S., Nolff, M., & Holland, J. P. (2024). Radiolabelled $^{177}$Lu-Bispidine-Trastuzumab for Targeting Human Epidermal Growth Factor Receptor 2 Positive Cancers. Chemistry, 30, e202303805. https://doi.org/10.1002/chem.202303805
Abstract
Abstract
Abstract
Radioimmunotherapy (RIT) is a promising alternative to conventional treatment options. Here, we present experimental work on the synthesis, radiochemistry, and in vivo performance of a lanthanoid-selective nonadentate bispidine ligand suitable for $^{177}$Lu$^{3+}$ ion complexation. The ligand (bisp,1) was derivatised with a photoactivatable aryl azide (ArN$_3$) group as a bioconjugation handle for light-induced labelling of proteins. Quantitative radiosynthesis of [$^{177}$Lu]Lu-1$^{+}$
Metrics
Downloads
Views
Additional indexing
Other titles
Other titles
Other titles
Creators (Authors)
- Cieslik, Patrick A
- Klingler, Simon
- Nolff, Mirja
- Holland, Jason P
Volume
Volume
Volume
Number
Number
Number
Page range/Item number
Page range/Item number
Page range/Item number
Item Type
Item Type
Item Type
In collections
Dewey Decimal Classifikation
Dewey Decimal Classifikation
Dewey Decimal Classifikation
Keywords
Language
Language
Language
Publication date
Publication date
Publication date
Date available
Date available
Date available
ISSN or e-ISSN
ISSN or e-ISSN
ISSN or e-ISSN
OA Status
OA Status
OA Status
Publisher DOI
Metrics
Downloads
Views
Citations
Cieslik, P. A., Klingler, S., Nolff, M., & Holland, J. P. (2024). Radiolabelled $^{177}$Lu-Bispidine-Trastuzumab for Targeting Human Epidermal Growth Factor Receptor 2 Positive Cancers. Chemistry, 30, e202303805. https://doi.org/10.1002/chem.202303805
